Applied Therapeutics Inc. (NASDAQ:APLT) Short Interest Update

Applied Therapeutics Inc. (NASDAQ:APLT) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 3,544,632 shares, a decline of 46.6% from the December 31st total of 6,633,907 shares. Currently, 2.3% of the shares of the company are short sold. Based on an average daily volume of 12,289,802 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 12,289,802 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.3% of the shares of the company are short sold.

Institutional Investors Weigh In On Applied Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP raised its position in Applied Therapeutics by 23.9% during the third quarter. Vestal Point Capital LP now owns 14,250,000 shares of the company’s stock worth $8,620,000 after acquiring an additional 2,750,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Applied Therapeutics by 7.8% during the 3rd quarter. Vanguard Group Inc. now owns 5,102,689 shares of the company’s stock worth $3,087,000 after purchasing an additional 368,676 shares in the last quarter. Deltec Asset Management LLC acquired a new position in shares of Applied Therapeutics during the 4th quarter worth approximately $385,000. PNC Financial Services Group Inc. acquired a new position in shares of Applied Therapeutics during the 3rd quarter worth approximately $1,755,000. Finally, UBS Group AG lifted its stake in Applied Therapeutics by 129.4% in the 3rd quarter. UBS Group AG now owns 1,905,625 shares of the company’s stock valued at $1,153,000 after buying an additional 1,074,980 shares in the last quarter. 98.31% of the stock is owned by institutional investors and hedge funds.

Applied Therapeutics Price Performance

APLT opened at $0.10 on Friday. Applied Therapeutics has a 1-year low of $0.09 and a 1-year high of $0.11. The stock has a market cap of $15.83 million, a P/E ratio of -1.03 and a beta of 2.08. The stock’s 50 day simple moving average is $0.14 and its 200 day simple moving average is $0.49.

Applied Therapeutics (NASDAQ:APLT) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. The firm had revenue of $1.00 million for the quarter, compared to analyst estimates of $0.25 million. Research analysts expect that Applied Therapeutics will post -0.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on APLT. Leerink Partners cut Applied Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. Robert W. Baird cut shares of Applied Therapeutics from an “outperform” rating to a “neutral” rating in a report on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Applied Therapeutics in a research report on Monday, December 29th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $1.25.

About Applied Therapeutics

Applied Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation.

The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia.